{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:27:49Z","timestamp":1793388469107,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00904-9","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:38:50Z","timestamp":1747766330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Rapamycin treatment for Alzheimer\u2019s disease and related dementias: a pilot phase 1 clinical trial"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-0938","authenticated-orcid":false,"given":"Mitzi M.","family":"Gonzales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-7186","authenticated-orcid":false,"given":"Valentina R.","family":"Garbarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany F.","family":"Kautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-1012","authenticated-orcid":false,"given":"Marisa","family":"Lopez-Cruzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-7771","authenticated-orcid":false,"given":"Candice E.","family":"Van Skike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-4461","authenticated-orcid":false,"given":"Gabriel A.","family":"De Erausquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-8568","authenticated-orcid":false,"given":"Veronica","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-2724","authenticated-orcid":false,"given":"Miranda E.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-4553","authenticated-orcid":false,"given":"Yingxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kraig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Dean","family":"Kellogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer\u2019s Association Report.","year":"2023","unstructured":"Alzheimer\u2019s Association Report. 2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 19, 1598\u20131695 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings, J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs 83, 569\u2013576 (2023).","journal-title":"Drugs"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3233\/JAD-215680","volume":"87","author":"A Salehipour","year":"2022","unstructured":"Salehipour, A., Bagheri, M., Sabahi, M., Dolatshahi, M. & Boche, D. Combination therapy in Alzheimer\u2019s disease: Is it time? J. Alzheimer\u2019s Dis. 87, 1433\u20131449 (2022).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.0000000000006745","volume":"92","author":"Y Hara","year":"2019","unstructured":"Hara, Y., McKeehan, N. & Fillit, H. M. Translating the biology of aging into novel therapeutics for Alzheimer disease. Neurology 92, 84\u201393 (2019).","journal-title":"Neurology"},{"key":"904_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. Cell 153, 1194\u20131217 (2013).","journal-title":"Cell"},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1474-9726.2012.00832.x","volume":"11","author":"JE Wilkinson","year":"2012","unstructured":"Wilkinson, J. E. et al. Rapamycin slows aging in mice. Aging Cell 11, 675\u2013682 (2012).","journal-title":"Aging Cell"},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11357-020-00274-1","volume":"43","author":"R Selvarani","year":"2021","unstructured":"Selvarani, R., Mohammed, S. & Richardson, A. Effect of rapamycin on aging and age-related diseases\u2014past and future. GeroScience 43, 1135\u20131158 (2021).","journal-title":"GeroScience"},{"key":"904_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/acel.12313","volume":"14","author":"KH Schreiber","year":"2015","unstructured":"Schreiber, K. H. et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 14, 265\u2013273 (2015).","journal-title":"Aging Cell"},{"key":"904_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101376","volume":"70","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Zhang, J. & Wang, S. The role of Rapamycin in healthspan extension via the delay of organ aging. Ageing Res. Rev. 70, 101376 (2021).","journal-title":"Ageing Res. Rev."},{"key":"904_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/jcbfm.2013.82","volume":"33","author":"AL Lin","year":"2013","unstructured":"Lin, A. L. et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer\u2019s disease. J. Cereb. Blood Flow. Metab. 33, 1412\u20131421 (2013).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1523\/JNEUROSCI.2144-20.2021","volume":"41","author":"CE Van Skike","year":"2021","unstructured":"Van Skike, C. E. et al. mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer\u2019s disease. J. Neurosci. 41, 4305\u20134320 (2021).","journal-title":"J. Neurosci."},{"key":"904_CR12","doi-asserted-by":"publisher","first-page":"e9979","DOI":"10.1371\/journal.pone.0009979","volume":"5","author":"P Spilman","year":"2010","unstructured":"Spilman, P. et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer\u2019s disease. PLoS One 5, e9979 (2010).","journal-title":"PLoS One"},{"key":"904_CR13","doi-asserted-by":"publisher","first-page":"13107","DOI":"10.1074\/jbc.M110.100420","volume":"285","author":"A Caccamo","year":"2010","unstructured":"Caccamo, A., Majumder, S., Richardson, A., Strong, R. & Oddo, S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107\u201313120 (2010).","journal-title":"J. Biol. Chem."},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.freeradbiomed.2021.04.025","volume":"169","author":"M Perluigi","year":"2021","unstructured":"Perluigi, M., Di Domenico, F., Barone, E. & Butterfield, D. A. mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic. Biol. Med. 169, 382\u2013396 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"904_CR15","doi-asserted-by":"publisher","unstructured":"Fiscon, G., Sibilio, P., Funari, A., Conte, F. & Paci, P. Identification of potential repurposable drugs in Alzheimer\u2019s disease exploiting a bioinformatics analysis. J. Pers. Med. https:\/\/doi.org\/10.3390\/jpm12101731 (2022).","DOI":"10.3390\/jpm12101731"},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/JAD-230526","volume":"95","author":"JD Silva","year":"2023","unstructured":"Silva, J. D., Taglialatela, G. & Jupiter, D. C. Reduced prevalence of dementia in patients prescribed tacrolimus, sirolimus, or cyclosporine. J. Alzheimers Dis. 95, 585\u2013597 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"904_CR17","doi-asserted-by":"crossref","unstructured":"Hou, S. J., Zhang, S. X., Li, Y., & Xu, S. Y. Rapamycin responds to Alzheimer\u2019s disease: a potential translational therapy. Clin. Inter. Aging 18, 1629\u20131639 (2023).","DOI":"10.2147\/CIA.S429440"},{"key":"904_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/1389200218666170607101622","volume":"18","author":"M Shoaib","year":"2017","unstructured":"Shoaib, M., Kamal, M. A. & Rizvi, S. M. D. Repurposed drugs as potential therapeutic candidates for the management of Alzheimer\u2019s disease. Curr. Drug Metab. 18, 842\u2013852 (2017).","journal-title":"Curr. Drug Metab."},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/thoraxjnl-2017-210872","volume":"73","author":"J Bee","year":"2018","unstructured":"Bee, J., Fuller, S., Miller, S. & Johnson, S. R. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax 73, 369\u2013375 (2018).","journal-title":"Thorax"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","volume":"105","author":"E Kraig","year":"2018","unstructured":"Kraig, E. et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp. Gerontol. 105, 53\u201369 (2018).","journal-title":"Exp. Gerontol."},{"key":"904_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40734-8","volume":"14","author":"J Mandrioli","year":"2023","unstructured":"Mandrioli, J. et al. Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. Nat. Commun. 14, 4970 (2023).","journal-title":"Nat. Commun."},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","volume":"6","author":"JB Mannick","year":"2014","unstructured":"Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med 6, 268ra179 (2014).","journal-title":"Sci. Transl. Med"},{"key":"904_CR23","doi-asserted-by":"publisher","unstructured":"Mannick, J. B. et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaq1564 (2018).","DOI":"10.1126\/scitranslmed.aaq1564"},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s11357-023-00818-1","volume":"45","author":"TL Kaeberlein","year":"2023","unstructured":"Kaeberlein, T. L. et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Geroscience 45, 2757\u20132768 (2023).","journal-title":"Geroscience"},{"key":"904_CR25","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy, T. F. et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8 (2008).","journal-title":"PLoS Med."},{"key":"904_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barth\u00e9lemy","year":"2019","unstructured":"Barth\u00e9lemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C. & Bateman, R. J. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer\u2019s disease. Front Aging Neurosci. 11, 121 (2019).","journal-title":"Front Aging Neurosci."},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvad\u00f3","year":"2024","unstructured":"Salvad\u00f3, G. et al. Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat. Aging 4, 694\u2013708 (2024).","journal-title":"Nat. Aging"},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand, A. L. et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res. Ther. 14, 195 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"904_CR30","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"904_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front. Psychol. 4, 863 (2013).","journal-title":"Front. Psychol."},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack, C. R. Jr. et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s. Dement. 7, 257\u2013262 (2011).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"904_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1041610297004870","volume":"9","author":"JC Morris","year":"1997","unstructured":"Morris, J. C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9, 173\u2013176 (1997).","journal-title":"Int. Psychogeriatr."},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/pharmaceutics13040470","volume":"13","author":"AN Sabo","year":"2021","unstructured":"Sabo, A. N. et al. Sirolimus pharmacokinetics variability points to the relevance of therapeutic drug monitoring in pediatric oncology. Pharmaceutics 13, 470 (2021).","journal-title":"Pharmaceutics"},{"key":"904_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/alz.12215","volume":"17","author":"D Wilcock","year":"2021","unstructured":"Wilcock, D. et al. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimers Dement 17, 704\u2013715 (2021).","journal-title":"Alzheimers Dement"},{"key":"904_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"904_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict, R. H. B., Schretlen, D., Groninger, L. & Brandt, J. Hopkins verbal learning test\u2013revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12, 43\u201355 (1998).","journal-title":"Clin. Neuropsychol."},{"key":"904_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0028-3932(95)00104-2","volume":"34","author":"PW Burgess","year":"1996","unstructured":"Burgess, P. W. & Shallice, T. Response suppression, initiation and strategy use following frontal lobe lesions. Neuropsychologia 34, 263\u2013272 (1996).","journal-title":"Neuropsychologia"},{"key":"904_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WAD.0000000000000223","volume":"32","author":"S Weintraub","year":"2018","unstructured":"Weintraub, S. et al. Version 3 of the Alzheimer Disease Centers\u2019 neuropsychological test battery in the uniform data set (UDS). Alzheimer Dis. Assoc. Disord. 32, 10\u201317 (2018).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"904_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jad.2019.08.053","volume":"259","author":"C Shin","year":"2019","unstructured":"Shin, C. et al. Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. J. Affect Disord. 259, 370\u2013375 (2019).","journal-title":"J. Affect Disord."},{"key":"904_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WAD.0b013e318191c7dd","volume":"23","author":"S Weintraub","year":"2009","unstructured":"Weintraub, S. et al. The Alzheimer\u2019s Disease Centers\u2019 uniform data set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord. 23, 91\u2013101 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"904_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. Jr., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323\u2013329 (1982).","journal-title":"J. Gerontol."},{"key":"904_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"904_CR44","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","volume":"29","author":"MM Gonzales","year":"2023","unstructured":"Gonzales, M. M. et al. Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial. Nat. Med. 29, 2481\u20132488 (2023).","journal-title":"Nat. Med."},{"key":"904_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat. Commun. 11, 1683 (2020).","journal-title":"Nat. Commun."},{"key":"904_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"904_CR47","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","volume":"17","author":"RM Laberge","year":"2015","unstructured":"Laberge, R. M. et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17, 1049\u20131061 (2015).","journal-title":"Nat. Cell Biol."},{"key":"904_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF02171742","volume":"2","author":"MA Wood","year":"1994","unstructured":"Wood, M. A. & Bierer, B. E. Rapamycin: biological and therapeutic effects, binding by immunophilins and molecular targets of action. Perspect. Drug Discov. Des. 2, 163\u2013184 (1994).","journal-title":"Perspect. Drug Discov. Des."},{"key":"904_CR49","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-018-0632-y","volume":"57","author":"N Srinivas","year":"2018","unstructured":"Srinivas, N., Maffuid, K. & Kashuba, A. D. M. Clinical pharmacokinetics and pharmacodynamics of drugs in the central nervous system. Clin. Pharmacokinet. 57, 1059\u20131074 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"904_CR50","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","volume":"56","author":"DD Shen","year":"2004","unstructured":"Shen, D. D., Artru, A. A. & Adkison, K. K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv. Drug Deliv. Rev. 56, 1825\u20131857 (2004).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"904_CR51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","volume":"82","author":"CM Hartford","year":"2007","unstructured":"Hartford, C. M. & Ratain, M. J. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther. 82, 381\u2013388 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"904_CR52","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1161\/HYPERTENSIONAHA.109.138818","volume":"54","author":"W Soesanto","year":"2009","unstructured":"Soesanto, W. et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 54, 1321\u20131327 (2009).","journal-title":"Hypertension"},{"key":"904_CR53","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.transproceed.2009.02.005","volume":"41","author":"F Reis","year":"2009","unstructured":"Reis, F. et al. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant. Proc. 41, 868\u2013873 (2009).","journal-title":"Transplant. Proc."},{"key":"904_CR54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.117.09456","volume":"70","author":"V Kumar","year":"2017","unstructured":"Kumar, V., Wollner, C., Kurth, T., Bukowy, J. D. & Cowley, A. W. Jr. Inhibition of Mammalian target of rapamycin complex 1 attenuates salt-induced hypertension and kidney injury in Dahl salt-sensitive rats. Hypertension 70, 813\u2013821 (2017).","journal-title":"Hypertension"},{"key":"904_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza, G. et al. Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors. Clin. Dev. Immunol. 2013, 403280 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"904_CR56","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/j.1600-6143.2004.00612.x","volume":"4","author":"JJ Augustine","year":"2004","unstructured":"Augustine, J. J. et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am. J. Transpl. 4, 2001\u20132006 (2004).","journal-title":"Am. J. Transpl."},{"key":"904_CR57","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ndt\/gfp674","volume":"25","author":"S Sofroniadou","year":"2010","unstructured":"Sofroniadou, S., Kassimatis, T. & Goldsmith, D. Anaemia, microcytosis and sirolimus\u2014Is iron the missing link? Nephrol. Dial. Transpl. 25, 1667\u20131675 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"904_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/gerona\/glz157","volume":"75","author":"PC Reifsnyder","year":"2020","unstructured":"Reifsnyder, P. C., Te, A. & Harrison, D. E. Differential effects of rapamycin on glucose metabolism in nine inbred strains. J. Gerontol. A Biol. Sci. Med. Sci. 75, 50\u201357 (2020).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"904_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","volume":"4","author":"K Sankhala","year":"2009","unstructured":"Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 4, 135\u2013142 (2009).","journal-title":"Target Oncol."},{"key":"904_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1168967","volume":"10","author":"S Granata","year":"2023","unstructured":"Granata, S. et al. mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation. Front Med. 10, 1168967 (2023).","journal-title":"Front Med."},{"key":"904_CR61","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","volume":"335","author":"DW Lamming","year":"2012","unstructured":"Lamming, D. W. et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638\u20131643 (2012).","journal-title":"Science"},{"key":"904_CR62","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1212\/WNL.0000000000206744","volume":"100","author":"S Stukas","year":"2023","unstructured":"Stukas, S. et al. Association of CSF and serum neurofilament light and glial fibrillary acidic protein, injury severity, and outcome in spinal cord injury. Neurology 100, e1221\u2013e1233 (2023).","journal-title":"Neurology"},{"key":"904_CR63","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol."},{"key":"904_CR64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/alz.12415","volume":"18","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement .18, 602\u2013611 (2022).","journal-title":"Alzheimers Dement"},{"key":"904_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-230799","volume":"98","author":"Z Li","year":"2024","unstructured":"Li, Z., Fan, Z. & Zhang, Q. The associations of phosphorylated tau 181 and tau 231 levels in plasma and cerebrospinal fluid with cognitive function in Alzheimer\u2019s disease: a systematic review and meta-analysis. J. Alzheimer\u2019s. Dis. 98, 13\u201332 (2024).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"904_CR66","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology 97, e1681\u2013e1694 (2021).","journal-title":"Neurology"},{"key":"904_CR67","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"904_CR68","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke, M. M. et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology 93, e252\u2013e260 (2019).","journal-title":"Neurology"},{"key":"904_CR69","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jalz.2019.01.015","volume":"15","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3, A. et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer\u2019s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 15, 742\u2013753 (2019).","journal-title":"Alzheimers Dement."},{"key":"904_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neulet.2007.03.064","volume":"419","author":"K Blennow","year":"2007","unstructured":"Blennow, K. et al. Longitudinal stability of CSF biomarkers in Alzheimer\u2019s disease. Neurosci. Lett. 419, 18\u201322 (2007).","journal-title":"Neurosci. Lett."},{"key":"904_CR71","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/0271678X15621575","volume":"37","author":"AL Lin","year":"2017","unstructured":"Lin, A. L. et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer\u2019s disease. J. Cereb. Blood Flow. Metab. 37, 217\u2013226 (2017).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"904_CR72","doi-asserted-by":"publisher","first-page":"e9979","DOI":"10.1371\/journal.pone.0009979","volume":"5","author":"P Spilman","year":"2010","unstructured":"Spilman, P. et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-\u03b2 levels in a mouse model of Alzheimer\u2019s disease. PLoS One 5, e9979 (2010).","journal-title":"PLoS One"},{"key":"904_CR73","doi-asserted-by":"publisher","first-page":"H693","DOI":"10.1152\/ajpheart.00570.2017","volume":"314","author":"CE Van Skike","year":"2018","unstructured":"Van Skike, C. E. et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer\u2019s disease and vascular cognitive impairment. Am. J. Physiol. Heart Circ. Physiol. 314, H693\u2013h703 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"904_CR74","doi-asserted-by":"publisher","unstructured":"Van Skike, C. E. et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell. https:\/\/doi.org\/10.1111\/acel.13057 (2019).","DOI":"10.1111\/acel.13057"},{"key":"904_CR75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neuroscience.2012.06.054","volume":"223","author":"J Halloran","year":"2012","unstructured":"Halloran, J. et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223, 102\u2013113 (2012).","journal-title":"Neuroscience"},{"key":"904_CR76","doi-asserted-by":"crossref","unstructured":"Caccamo, A., Majumder, S., Richardson, A., Strong, R. & Oddo, S. Molecular interplay between mTOR, A\u03b2 and tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107\u201313120 (2010).","DOI":"10.1074\/jbc.M110.100420"},{"key":"904_CR77","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/brainsci11101258","volume":"11","author":"GP Paraskevas","year":"2021","unstructured":"Paraskevas, G. P. & Kapaki, E. Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in the era of disease-modifying treatments. Brain Sci. 11, 1258 (2021).","journal-title":"Brain Sci."},{"key":"904_CR78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s. Res. Ther. 11, 34 (2019).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"904_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01019-z","volume":"8","author":"K Horie","year":"2020","unstructured":"Horie, K. et al. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathol. Commun. 8, 149 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"904_CR80","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"904_CR81","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.yexcr.2005.12.011","volume":"312","author":"P Fang","year":"2006","unstructured":"Fang, P., Hwa, V. & Rosenfeld, R. G. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp. Cell Res. 312, 1229\u20131239 (2006).","journal-title":"Exp. Cell Res."},{"key":"904_CR82","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2666-7568(21)00062-3","volume":"2","author":"JB Mannick","year":"2021","unstructured":"Mannick, J. B. et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. Lancet Healthy Longev. 2, e250\u2013e262 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"904_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/alz.12399","volume":"18","author":"HS Yang","year":"2022","unstructured":"Yang, H. S. et al. Plasma IL-12\/IFN-\u03b3 axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimers Dement. 18, 645\u2013653 (2022).","journal-title":"Alzheimers Dement."},{"key":"904_CR84","doi-asserted-by":"publisher","first-page":"e64971","DOI":"10.1371\/journal.pone.0064971","volume":"8","author":"R Leung","year":"2013","unstructured":"Leung, R. et al. Inflammatory proteins in plasma are associated with severity of Alzheimer\u2019s disease. PloS one 8, e64971 (2013).","journal-title":"PloS one"},{"key":"904_CR85","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes, C. et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768\u2013774 (2009).","journal-title":"Neurology"},{"key":"904_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107101","volume":"201","author":"C Ceci","year":"2024","unstructured":"Ceci, C. et al. The VEGFs\/VEGFRs system in Alzheimer\u2019s and Parkinson\u2019s diseases: Pathophysiological roles and therapeutic implications. Pharmacol. Res. 201, 107101 (2024).","journal-title":"Pharmacol. Res."},{"key":"904_CR87","doi-asserted-by":"publisher","unstructured":"Zakariaee, S. S., Naderi, N. & Azizi, E. Association of vascular endothelial growth factor levels with risk of Alzheimer\u2019s disease: a systematic review and meta-analysis. J. Preven. Alzheimer\u2019s Dis. https:\/\/doi.org\/10.14283\/jpad.2024.18 (2024).","DOI":"10.14283\/jpad.2024.18"},{"key":"904_CR88","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chest.2017.05.012","volume":"153","author":"AM Taveira-DaSilva","year":"2018","unstructured":"Taveira-DaSilva, A. M., Jones, A. M., Julien-Williams, P., Stylianou, M. & Moss, J. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest 153, 124\u2013132 (2018).","journal-title":"Chest"},{"key":"904_CR89","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1161\/STROKEAHA.123.044172","volume":"55","author":"KE Foley","year":"2024","unstructured":"Foley, K. E. & Wilcock, D. M. Soluble biomarkers of cerebrovascular pathologies. Stroke 55, 801\u2013811 (2024).","journal-title":"Stroke"},{"key":"904_CR90","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1002\/alz.12974","volume":"19","author":"JD Hinman","year":"2023","unstructured":"Hinman, J. D. et al. Placental growth factor as a sensitive biomarker for vascular cognitive impairment. Alzheimer\u2019s. Dement. 19, 3519\u20133527 (2023).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"904_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0271678X18807309","volume":"39","author":"G Hadley","year":"2019","unstructured":"Hadley, G. et al. Rapamycin in ischemic stroke: Old drug, new tricks? J. Cereb. Blood Flow. Metab. 39, 20\u201335 (2019).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"904_CR92","doi-asserted-by":"publisher","first-page":"e0142340","DOI":"10.1371\/journal.pone.0142340","volume":"10","author":"R Siman","year":"2015","unstructured":"Siman, R., Cocca, R. & Dong, Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One 10, e0142340 (2015).","journal-title":"PLoS One"},{"key":"904_CR93","first-page":"779","volume":"18","author":"N Cappoli","year":"2019","unstructured":"Cappoli, N. et al. The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. Excli j. 18, 779\u2013798 (2019).","journal-title":"Excli j."},{"key":"904_CR94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4062\/biomolther.2012.089","volume":"21","author":"HE Han","year":"2013","unstructured":"Han, H. E., Kim, T. K., Son, H. J., Park, W. J. & Han, P. L. Activation of autophagy pathway suppresses the expression of iNOS, IL6 and cell death of LPS-stimulated microglia cells. Biomol. Ther. (Seoul.) 21, 21\u201328 (2013).","journal-title":"Biomol. Ther. (Seoul.)"},{"key":"904_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","volume":"16","author":"R Tarawneh","year":"2024","unstructured":"Tarawneh, R. & Pankratz, V. S. The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY-AD and beyond. Alzheimer\u2019s. Res. Ther. 16, 37 (2024).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"904_CR96","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1016\/j.transproceed.2009.08.050","volume":"41","author":"UE Lang","year":"2009","unstructured":"Lang, U. E. et al. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transpl. Proc. 41, 4285\u20134288 (2009).","journal-title":"Transpl. Proc."},{"key":"904_CR97","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41514-017-0018-7","volume":"3","author":"I Alfaras","year":"2017","unstructured":"Alfaras, I. et al. Health benefits of late-onset metformin treatment every other week in mice. NPJ Aging Mech. Dis. 3, 16 (2017).","journal-title":"NPJ Aging Mech. Dis."},{"key":"904_CR98","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1080\/15548627.2019.1615823","volume":"15","author":"JM Carosi","year":"2019","unstructured":"Carosi, J. M. & Sargeant, T. J. Rapamycin and Alzheimer disease: A double-edged sword? Autophagy 15, 1460\u20131462 (2019).","journal-title":"Autophagy"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00904-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T20:03:06Z","timestamp":1747771386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00904-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00904-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mitzi M. Gonzales reports personal stock in AbbVie. Miranda Orr has a patent, Biosignature and Therapeutic Approach for Neuronal Senescence, pending. Randall J. Bateman reports a relationship with C2N Diagnostics and receives income from serving on the scientific advisory board as a co-founder. Randall J. Bateman has received research funding from Avid Radiopharmaceuticals, Janssen, Roche\/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (Stable Isotope Labeling Kinetics, Blood Plasma Assay, and Methods of Diagnosing AD with Phosphorylation Changes) licensed by Washington University to C2N Diagnostics. Dr. Seshadri has consulted for Eisai and Biogen outside the current work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}